Patrick D. McGillivray

Patrick D. McGillivray

Auto-generated profile, based on publicly available information

Patrick D. McGillivray

Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520, USA; Yale School of Medicine, Yale University, New Haven, CT 06510, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2020 in Cell
Verified
Journal Article
Closed access
SKSushant Kumar
Sushant Kumar
JWJonathan Warrell
Jonathan Warrell
SLShantao Li
Shantao Li
PMPatrick D. McGillivray
Patrick D. McGillivray
WMWilliam Meyerson
William Meyerson
MGMark B. Gerstein
Mark B. Gerstein

1 September 2018 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
DUDaiki Ueno
Daiki Ueno
ZXZuoquan Xie
Zuoquan Xie
MBMarta Boeke
Marta Boeke
JSJamil Syed
Jamil Syed
KNKevin A. Nguyen
Kevin A. Nguyen
BSBrian Shuch
Brian Shuch
Purpose: Tumor heterogeneity may represent a barrier to preoperative genomic characterization by needle biopsy in clear cell renal cell carcinoma (ccRCC). The extent of heterogeneity in small renal tumors remains unknown. Therefore, we set out to evaluate heterogeneity in resected large and small renal tumors. Experimental Design: We conducted a study from 2013 to 2016 that evaluated 47 consecutive ccRCC tumors resected during radical or partial nephrectomy. Cases were designated as small (7 cm) tumors. Each tumor had three regions sampled. Copy-number variation (CNV) was assessed and gene expression analysis was performed to characterize the clear-cell A and B (ccA/ccB) profile and the cell-cycle progression (CCP) score. Genomic heterogeneity between three regions was evaluated using CNV subclonal events, regional expression profiles, and correlation between gene expression. Results: Twenty-three small and 24 large tumors were analyzed. Total CNVs and subclonal CNVs events were less frequent in small tumors (P < 0.001). Significant gene expression heterogeneity was observed for both CCP scores and ccA/ccB classifications. Larger tumors had more variance in CCP scores (P = 0.026). The distribution of ccA/ccB differed between small and large tumors with mixed ccA/ccB tumors occurring more frequently in the larger tumors (P = 0.024). Analysis of five mixed tumors (with both ccA/ccB regions) demonstrated the more aggressive ccB phenotype had greater CNV events (P = 0.014). Conclusions: Small renal tumors have much less genomic complexity and fewer subclonal events. Pretreatment genomic characterization with single-needle biopsy in small tumors may be useful to assess biologic potential and may influence therapy. Clin Cancer Res; 24(17); 4137–44. ©2018 AACR.

12 March 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
SKSushant Kumar
Sushant Kumar
JWJonathan Warrell
Jonathan Warrell
SLShantao Li
Shantao Li
PMPatrick D. McGillivray
Patrick D. McGillivray
WMWilliam Meyerson
William Meyerson
MGMark B. Gerstein
Mark B. Gerstein
The Pan-cancer Analysis of Whole Genomes (PCAWG) project provides an unprecedented opportunity to comprehensively characterize a vast set of uniformly annotated coding and non-coding mutations present in thousands of cancer genomes. Classical models of cancer progression posit that only a small number of these mutations strongly drive tumor progression and that the remaining ones (termed “putative passengers”) are inconsequential for tumorigenesis. In this study, we leveraged the comprehensive variant data from PCAWG to ascertain the molecular functional impact of each variant. The impact distribution of PCAWG mutations shows that, in addition to high- and low-impact mutations, there is a group of medium-impact putative passengers predicted to influence gene activity. Moreover, the predicted impact relates to the underlying mutational signature: different signatures confer divergent impact, differentially affecting distinct regulatory subsystems and gene categories. We also find that impact varies based on subclonal architecture (i.e., early vs. late mutations) and can be related to patient survival. Finally, we note that insufficient power due to limited cohort sizes precludes identification of weak drivers using standard recurrence-based approaches. To address this, we adapted an additive effects model derived from complex trait studies to show that aggregating the impact of putative passenger variants (i.e. including yet undetected weak drivers) provides significant predictability for cancer phenotypes beyond the PCAWG identified driver mutations (12.5% additive variance). Furthermore, this framework allowed us to estimate the frequency of potential weak driver mutations in the subset of PCAWG samples lacking well-characterized driver alterations.

7 February 2017 in bioRxiv
Verified
Preprint
Open access
PDF file
SBSuganthi Balasubramanian
Suganthi Balasubramanian
YFYao Fu
Yao Fu
MPMayur Pawashe
Mayur Pawashe
PMPatrick McGillivray
Patrick McGillivray
MJMike Jin
Mike Jin
MGMark Gerstein
Mark Gerstein
Variants predicted to result in the loss of function (LoF) of human genes have attracted interest because of their clinical impact and surprising prevalence in healthy individuals. Here, we present ALoFT (Annotation of Loss-of-Function Transcripts), a method to annotate and predict the disease-causing potential of LoF variants. Using data from Mendelian disease-gene discovery projects, we show that ALoFT can distinguish between LoF variants deleterious as heterozygotes and those causing disease only in the homozygous state. Investigation of variants discovered in healthy populations suggests that each individual carries at least two heterozygous premature stop alleles that could potentially lead to disease if present as homozygotes. When applied to de novo pLoF variants in autism-affected families, ALoFT distinguishes between deleterious variants in patients and benign variants in unaffected siblings. Finally, analysis of somatic variants in > 6,500 cancer exomes shows that pLoF variants predicted to be deleterious by ALoFT are enriched in known driver genes.